Key Takeaways

• A Maryland-based vein treatment operator and CEO agreed to a $4 million settlement over alleged medically unnecessary venous procedures billed to Medicare, Medicaid, and TRICARE across six years.
• Coverage criteria for chronic venous insufficiency procedures require failed conservative management and exclude cosmetic-only interventions, forming the basis for alleged false claims involving sclerotherapy and thermal ablation techniques.
• Whistleblower-initiated enforcement underpinned the case, with two former employees receiving $752,000, reinforcing FCA-driven oversight of outpatient procedural utilization.
• Extended-release weekly injectable buprenorphine increased illicit opioid abstinence and reduced serious maternal adverse events in pregnancy versus daily sublingual therapy, with comparable neonatal opioid withdrawal syndrome outcomes.
• A CGM-informed algorithm enabling weekly insulin dose adjustments improved type 2 diabetes time-in-range to 75.3% over 16 weeks, substantially outperforming standard self-monitoring in a 30-participant randomized trial.

SHOW MORE

Federal settlement resolves six years of alleged billing fraud targeting Medicare, Medicaid and TRICARE.

A Maryland-based vein treatment company and its physician CEO have agreed to pay $4 million to settle federal allegations that they billed Medicare, Medicaid and TRICARE for medically unnecessary procedures over a six-year period. CVR Management, LLC — which manages the Center for Vein...

Read Full Story: https://news.google.com/rss/articles/CBMi3AJBVV95cUxNTEktN0ZJTmVkeEpkZjFMY0Yz...